Knockout animals manifesting hyperlipidemia

• US 7,402,730 B1
• Filed: 02/03/2006
• Issued: 07/22/2008
• Est. Priority Date: 02/03/2005
• Status: Active Grant

• Current Assignee: Lexicon Pharmaceuticals, Inc. (The Invus Group LLC)
• Original Assignee: Lexicon Pharmaceuticals, Inc. (The Invus Group LLC)
• Inventors: Sparks, Mary Jean, Huang, Wenhu
• Primary Examiner(s): Woitach; Joesph
• Assistant Examiner(s): HIRIYANNA, KELAGINAMANE T
• Application Number:
  US11/347,838
• Time in Patent Office: 900 Days
• Field of Search: None
• US Class Current: 800/18
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2267/0306 Animal model for genetic diseases
• CPC Class Codes: A01K 2267/0362 Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
• CPC Class Codes: A01K 67/0276 Knock-out vertebrates
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Abstract

Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal antibodies against GHP1.

Claims

1. A transgenic mouse whose genome comprises a disruption of the GPI-anchored HDL Binding protein 1 (GHP1) gene, wherein said mouse exhibits an increase in serum cholesterol levels when compared to a control mouse.

2. A transgenic mouse according to claim 1, homozygous for said gene disruption, wherein said mouse lacks any expression of GHP1 protein and exhibits hypertriglyceridemia as compared to a control mouse, and wherein the mouse is able to generate antibodies that selectively bind to GHP1.